ERBB2 and breast cancer: Companion diagnostics are a prerequisite for receiving the corresponding therapeutic product, which is exemplified by the human epidermal growth factor receptor 2 (HER2) gene expression assessment by immunohistochemistry (IHC) in patients with breast cancer to determine whether they are eligible for trastuzumab treatment [4].